# Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

> **NCT07672782** · PHASE2 · NOT_YET_RECRUITING · sponsor: **GOG Foundation** · enrollment: 28 (estimated)

## Conditions studied

- Vulvar Carcinoma
- Recurrent or Metastatic Vulvar Cancer
- Squamous Cell Carcinoma Vulva

## Interventions

- **DRUG:** Tisotumab Vedotin

## Key facts

- **NCT ID:** NCT07672782
- **Lead sponsor:** GOG Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2029-03
- **Final completion:** 2029-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672782, "Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*